Answers are grounded in this paper and cite their sources.
BACKGROUND: BRAF V600E-mutant colorectal cancer (CRC) has aggressive behavior and limited therapeutic options. We investigated whether dual-specificity phosphatase 4 (DUSP4) contributes to this phenotype and defined its molecular mechanism. METHODS: DepMap and GEO data were integrated to nominate BRAF V600E-selective candidates. DUSP4 expression was validated in 30 paired tumors/normal tissues and an independent cohort (n = 326). Gain/loss-of-function studies were performed in HT29/RKO cells and xenografts. IP-MS, co‑IP, immunofluorescence, cycloheximide chase, inhibitor assays, and ubiquitination assays defined the mechanism. CD8+ T cells were analyzed by flow cytometry and chemokines by ELISA. RESULTS: DUSP4 was preferentially expressed in BRAF V600E‑mutant CRC and associated with nodal (P = 0.005) and distant metastasis (P = 0.019), and shorter overall survival. High DUSP4 independently predicted mortality [HR=2.102, 95%CI 1.395-3.165, P < 0.001]. Overexpression promoted proliferation, migration, and xenograft growth; knockdown produced opposite effects. Mechanistically, DUSP4 reduced PTEN protein stability and activated PI3K-AKT. DUSP4 recruited E3 ligase TRIM27, promoting K48‑linked polyubiquitination and proteasomal degradation of PTEN. TRIM27 manipulation partially rescued DUSP4‑dependent phenotypes. In vitro, DUSP4-overexpressing CRC cells impaired CD8+ T cell function, as evidenced by decreased expression of IFN-γ, GZMB, and CD107a. DUSP4 overexpression was associated with downregulated CXCL9/16, IFN-γ, TNF-α, and IL-2, and upregulated IL-10, effects partially reversed by PTEN overexpression. CONCLUSIONS: DUSP4 is preferentially expressed in BRAF V600E-mutant CRC and independently predicts poor prognosis. It promotes tumor progression via a novel TRIM27-PTEN-PI3K-AKT axis, and modulates the immune microenvironment by impairing CD8+ T cell function. DUSP4 may serve as a candidate prognostic biomarker and warrants further investigation as a potential therapeutic target.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: